Inventor · disambiguated record
John H. Sampson
Also filed as: SAMPSON JOHN H · SAMPSON JOHN HOWARD · SAMPSON John
25 granted patents·13 pending applications·157 citations·filing 1997–2022
96Inventor score
Files withUNIV DUKE31SAMPSON JOHN H4BIGNER DARELL D1SCHMITTLING ROBERT J1THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES1
Top patents by PatentIndex Score
38 records- 0197US11389530B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2020·Granted Jul 19, 2022·5 cites·34 claims
- 0297US11376322B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2020·Granted Jul 5, 2022·5 cites·34 claims
- 0397US11364295B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2020·Granted Jun 21, 2022·5 cites·34 claims
- 0497US11351248B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2020·Granted Jun 7, 2022·5 cites·34 claims
- 0597US10632190B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2017·Granted Apr 28, 2020·12 cites·55 claims
- 0697US9764026B2Compositions, methods, and kits for eliciting an immune responseUNIV DUKE·Filed 2015·Granted Sep 19, 2017·19 cites·8 claims
- 0796US9011835B2Compositions, methods, and kits for eliciting an immune responseUNIV DUKE·Filed 2013·Granted Apr 21, 2015·18 cites·10 claims
- 0895US8425898B2Compositions, methods, and kits for eliciting an immune responseSAMPSON JOHN H·Filed 2009·Granted Apr 23, 2013·26 cites·8 claims
- 0992US11813298B2Oncolytic poliovirus for human tumorsUNIV DUKE·Filed 2022·Granted Nov 14, 2023·1 cites·18 claims
- 1092US11406677B2Oncolytic poliovirus for human tumorsUNIV DUKE·Filed 2020·Granted Aug 9, 2022·3 cites·25 claims
- 1192US10799543B2Oncolytic poliovirus for human tumorsUNIV DUKE·Filed 2019·Granted Oct 13, 2020·4 cites·31 claims
- 1288US10398743B2Oncolytic poliovirus for human tumorsUNIV DUKE·Filed 2017·Granted Sep 3, 2019·5 cites·22 claims
- 1388US9974848B2Tetanus toxoid and CCL3 improve DC vaccinesUNIV DUKE·Filed 2014·Granted May 22, 2018·8 cites·31 claims
- 1484US12070496B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2022·Granted Aug 27, 2024·0 cites·34 claims
- 1584US9249217B2Bispecific EGFRvIII x CD3 antibody engaging moleculesBIGNER DARELL D·Filed 2011·Granted Feb 2, 2016·10 cites·6 claims
- 1684US2022401552A1Compositions, Methods and Kits for Eliciting an Immune ResponseUNIV DUKE·Filed 2022·Application pending·0 cites
- 1783US2022387582A1Compositions, Methods and Kits for Eliciting an Immune ResponseUNIV DUKE·Filed 2022·Application pending·0 cites
- 1883US2022370602A1Compositions, Methods and Kits for Eliciting an Immune ResponseUNIV DUKE·Filed 2022·Application pending·0 cites
- 1981US9950056B2Compositions, methods and kits for eliciting an immune responseUNIV DUKE·Filed 2014·Granted Apr 24, 2018·5 cites·26 claims
- 2076US10053514B2Human bispecific EGFRvIII and CD3 antibody engaging moleculesUNIV DUKE·Filed 2014·Granted Aug 21, 2018·3 cites·8 claims
- 2172US11684662B2Tetanus toxoid and CCL3 improve DC vaccinesUNIV DUKE·Filed 2021·Granted Jun 27, 2023·0 cites·23 claims
- 2268US11071777B2Tetanus toxoid and CCL3 improve DC vaccinesUNIV DUKE·Filed 2018·Granted Jul 27, 2021·0 cites·16 claims
- 2366US2015118181A1Concurrent Chemotherapy and ImmunotherapySAMPSON JOHN H·Filed 2014·Application pending·0 cites
- 2465US9399662B2Concurrent chemotherapy and immunotherapySAMPSON JOHN H·Filed 2006·Granted Jul 26, 2016·0 cites·2 claims
- 2563US2011236345A1Composition and methods for eliciting an immune responseUNIV DUKE·Filed 2009·Application pending·0 cites
- 2661US8900816B2Assay for anti-EGFRvIII antibodiesSCHMITTLING ROBERT J·Filed 2008·Granted Dec 2, 2014·3 cites·16 claims
- 2761US2016030497A1Oncolytic poliovirus for human tumorsUNIV DUKE·Filed 2013·Application pending·0 cites
- 2859US2009004742A1Selection of antigen-specific t cellsUNIV DUKE·Filed 2008·Application pending·0 cites
- 2958US2018215789A1Concurrent Chemotherapy and ImmunotherapyUNIV DUKE·Filed 2018·Application pending·0 cites
- 3057US6503503B1Allogeneic cellular vaccineUNIV DUKE·Filed 1997·Granted Jan 7, 2003·20 cites·13 claims
- 3154US2012244145A1Enhanced immunological responsesSAMPSON JOHN H·Filed 2011·Application pending·0 cites
- 3248US9676858B2Human bispecific EGFRvIII antibody and CD3 engaging moleculesUNIV DUKE·Filed 2013·Granted Jun 13, 2017·0 cites·7 claims
- 3348US2021309750A1Enhanced Delivery of Drugs and Other Compounds to the Brain and Other TissuesUNIV DUKE·Filed 2019·Application pending·0 cites
- 3447US2015307614A1Enhanced immunological responsesUNIV DUKE·Filed 2015·Application pending·0 cites
- 3546US2018362659A1Certain Improved Human Bispecific EGFRvIII Antibody Engaging MoleculesTHE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES·Filed 2018·Application pending·0 cites
- 3645US8691960B2Oxidoreductases for enantioselective reactionsUNIV DUKE·Filed 2013·Granted Apr 8, 2014·0 cites·20 claims
- 3744US2011135637A1Trimodal cancer therapyUNIV DUKE·Filed 2010·Application pending·0 cites
- 3842US10744171B2Sequential anti-cancer treatmentUNIV DUKE·Filed 2017·Granted Aug 18, 2020·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when John H. Sampson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →